DENYES NANCY 4
4 · aTYR PHARMA INC · Filed Feb 7, 2022
Insider Transaction Report
Form 4
aTYR PHARMA INCLIFE
DENYES NANCY
General Counsel
Transactions
- Award
Employee Stock Option (right to buy)
2022-02-03+21,500→ 21,500 totalExercise: $5.52Exp: 2032-02-03→ Common Stock (21,500 underlying) - Award
Restricted Stock Units
2022-02-03+10,750→ 10,750 total→ Common Stock (10,750 underlying)
Footnotes (3)
- [F1]The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 3, 2022, such that this option will be fully exercisable on February 3, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
- [F2]Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
- [F3]The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.